Product Description
Mechanisms of Action: PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Croatia | Iceland | Ireland | Latvia | Netherlands | Poland | Portugal | Romania | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: Leiden University Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension|Atrial Fibrillation|Acute Coronary Syndrome|Stroke
Phase 3: Hypertension|Type 1 Diabetes|Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
114180 | P4 |
Unknown Status |
Stroke |
2031-09-02 |
|
BA-SCAD | P4 |
Unknown Status |
Unknown |
2026-02-28 |
|
WOEST 3 trial | P4 |
Active, not recruiting |
Acute Coronary Syndrome|Atrial Fibrillation |
2025-02-17 |
|
ASPIRETENSION | P4 |
Completed |
Hypertension |
2013-10-01 |